11:09:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMid Cap Stockholm
Q-linea är verksamma inom medicinteknik. Bolaget är specialiserade inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har sitt huvudkontor i Uppsala.


2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 Ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2021-03-10 12:56:00

Q-linea AB (publ) (OMX:QLINEA), today announced that the company’s global sales partner Thermo Fisher Scientific has placed their first order on ASTar® instruments and consumables. The value of the order exceeds SEK 8 million.

ASTar is a fully automatic system for antibiotic susceptibility testing (AST) with little hands-on time, ease-of-use and capabilities to deliver a broad answer within approximately six hours for positive blood cultures.

This order aims to enable commercial readiness for the first customer orders after launch. Commercial launch can take place as soon as the clinical study is finalized and ASTar is CE-IVD approved. ASTar´s first application is focused on improving the diagnostics for patients with blood stream infections, where sepsis is the most common condition.

The value of the first order from Thermo Fisher Scientific exceeds SEK 8 million. The structure of the order also includes a pre-payment for a binding order for the next six months.

Both Thermo Fisher Scientific and Q-linea believe in a strong growth for ASTar and aim for a long term successful and strong ramp-up after the first controlled launch phase.

“We are of course very excited to see the first order coming in before the completion of the clinical study. This enables us together to be ready for launch and shows the trust our partner has in a successful outcome of the clinical study. I also think that the structure with binding orders and pre-payment is important as we move into the commercial phase for Q-linea,” said Jonas Jarvius, CEO of Q-linea.